IP Library Granted Patent US 9,206,442
Granted Patent B2
US 9,206,442 · App. 13/457,791 · Granted Dec 8, 2015

Method for enzymatic treatment of tissue products

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,206,442
App. No.
13/457,791
Granted
Dec 8, 2015
Kind
B2
Abstract

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix.

Claims (22)

1. A method for increasing pliability in a tissue matrix, comprising:

selecting a collagen-containing tissue matrix, and

contacting the tissue matrix with an effective amount of proteolytic enzyme under conditions that produce an increased level of pliability in the tissue matrix;

wherein the enzyme is at least one selected from bromelain, papain, ficin, or actinidin;

wherein the collagen-containing tissue matrix includes a dermal tissue matrix that does not contain epidermis; and

wherein the tissue matrix is incubated in a decellularizing solution.

2. The method of claim 1 , wherein the tissue matrix is an acellular tissue matrix.

3. The method of claim 1 , wherein the tissue is selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.

4. The method of claim 1 , wherein the enzyme is bromelain.

5. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, burst strength, thermal transition temperature.

6. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that increase the porosity of the tissue matrix.

7. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not cause a statistically significant reduction in at least one of tensile strength, tear strength, suture strength, creep resistance, or thermal transition temperature.

8. A method for increasing pliability in a tissue matrix, comprising:

selecting a collagen-containing acellular tissue matrix, and

contacting the tissue matrix with an effective amount of proteolytic enzyme under conditions that produce an increased level of pliability in the tissue matrix;

wherein the enzyme is at least one selected from bromelain, papain, ficin, or actinidin;

wherein the collagen-containing tissue matrix includes a dermal tissue matrix that does not contain epidermis; and

wherein the tissue matrix is incubated in a decellularizing solution.

9. The method of claim 8 , wherein the acellular tissue matrix is selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.

10. The method of claim 8 , wherein the enzyme is bromelain.

11. The method of claim 8 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, burst strength, or thermal transition temperature.

12. The method of claim 8 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not cause a statistically significant reduction in at least one of tensile strength, tear strength, suture strength, creep resistance, or thermal transition temperature.

Assignments (7)
RELEASE OF SECURITY INTEREST 040098/0268 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0554 →
RELEASE OF SECURITY INTEREST 040291/0237 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0702 →
RELEASE OF SECURITY INTEREST 037845/0497 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0603 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
SECURITY INTEREST Recorded Feb 17, 2016
From: KINETIC CONCEPTS, INC.; KCI USA, INC.; ACELITY L.P. INC.; CHIRON HOLDINGS, INC.; CHIRON TOPCO, INC.; KCI ANIMAL HEALTH, LLC; KCI HOLDING COMPANY, INC.; KCI HOMECARE, INC.; KCI IMPORTS, INC.; KCI INTERNATIONAL, INC.; KCI LICENSING, INC.; KCI PROPERTIES LIMITED; KCI REAL HOLDINGS, L.L.C.; KCI REAL PROPERTY LIMITED; KCI USA REAL HOLDINGS, L.L.C.; LIFECELL CORPORATION; TECHNIMOTION, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 037845/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2012
From: CHEN, YI
To: LIFECELL CORPORATION
Reel/Frame 028451/0031 →